Drug intelligence / Profile preview

ALMB-0178

Development stage: Preclinical
Lead developer: AlaMab Therapeutics

Overview

ALMB-0178 is an investigational drug candidate developed by Alamab Therapeutics. It is currently in preclinical development and is being explored for the treatment of neoplasms (cancers). Detailed information about its mechanism of action, molecular target, or modality has not been publicly disclosed as of now[1].

Beyond the preview

Go deeper on ALMB-0178.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALMB-0178.

Explore the full profile